- Home
- DAWN vs EML Comparison
DAWN vs EML Comparison
Compare DAWN & EML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAWN | EML |
|---|---|---|
| Founded | 2018 | 1858 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 119.2M |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | DAWN | EML |
|---|---|---|
| Price | $21.29 | $20.15 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $26.00 | N/A |
| AVG Volume (30 Days) | ★ 5.7M | 14.3K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.14% |
| EPS Growth | N/A | ★ 185.40 |
| EPS | N/A | ★ 1.17 |
| Revenue | $158,182,000.00 | ★ $248,970,345.00 |
| Revenue This Year | $53.52 | $19.05 |
| Revenue Next Year | $27.10 | N/A |
| P/E Ratio | ★ N/A | $17.59 |
| Revenue Growth | ★ 20.60 | N/A |
| 52 Week Low | $5.64 | $17.61 |
| 52 Week High | $21.40 | $26.78 |
Technical Indicators
Market Signals| Indicator | DAWN | EML |
|---|---|---|
| Relative Strength Index (RSI) | 82.06 | 67.64 |
| Support Level | $6.45 | $18.03 |
| Resistance Level | N/A | $20.93 |
| Average True Range (ATR) | 0.60 | 0.64 |
| MACD | 1.13 | 0.20 |
| Stochastic Oscillator | 99.04 | 73.24 |
Price Performance
Historical ComparisonAbout DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.